MPM BIOVENTURES III PARALLEL FUND 4
4 · RIGEL PHARMACEUTICALS INC · Filed Aug 17, 2004
Insider Transaction Report
Form 4
MPM BIOVENTURES III QP LP
10% Owner
Transactions
- Sale
Common Stock
2004-08-13$22.30/sh−10,000$223,000→ 1,824,423 total(indirect: See Footnote)
Footnotes (2)
- [F1]See Form 4 filed for Luke Evnin for additional members of this joint filing. The shares were sold as follows: 560 by MPM BioVentures III, L.P. ("BVIII"); 8,324 by MPM BioVentures III-QP, L.P. ("BVIII QP"); 704 by MPM BioVentures III GmbH & Co. Beteiligungs KG ("BVIII KG"); 251 by MPM BioVentures III Parallel Fund, L.P. ("BVIII PF"); and 161 MPM Asset Management Investors 2003 BVIII LLC ("BVAM LLC"). MPM BioVentures III GP, L.P. ("BVIII GP") and MPM BioVentures III LLC ("BVIII LLC") are the direct and indirect partners of BVIII, BVIII QP, BVIII PF and BVIII KG.
- [F2]The shares are held as follows: 102,063 BVIII; 1,517,998 by BVIII QP; 128,291 by BVIII KG; 45,846 by BVIII PF; 29,399 by BVAM LLC; and 826 by Kurt Wheeler. Luke Evnin, Ansbert Gadicke, Nicholas Galakatos, Dennis Henner, Nicholas Simon, III, Michael Steinmetz and Kurt Wheeler are the members of BVIII LLC and BVAM LLC. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.